ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 432

Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study-

Tadashi Okano1, Kentaro Inui2, Masahiro Tada3, Yuko Sugioka4, Kenji Mamoto1, Tatsuya Koike4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orthopedic surgery, Osaka City General Hospital, Osaka, Japan, 4Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biologic drugs, methotrexate (MTX), remission and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The latest recommendations for the treatment of rheumatoid arthritis (RA) focus on the achievement of clinical remission. However, joints with subclinical positive power Doppler (PD) signals in ultrasonography (US) might be exposed to the risk of joint damage progression even after the achievement of clinical remission. The aim of this study was to assess subclinical synovitis by US and evaluate the effects of additional intensive treatment for preventing joint damage among RA patients in clinical remission.

Methods:

This study was based on the SCRUM (suppress the joint destruction in clinical remission patients who have active synovitis of ultrasonographic assessment by increasing the dose of methotrexate) study, an open-label, randomized trial. US examination was performed consecutively for 134 patients with RA in clinical remission defined as DAS (Disease activity score) 28<2.6. US assessment was performed at 34 synovial sites in 30 joints. The gray scale (GS) and PD signals were scored in each joint using a semi-quantitative scale from 0 to 3. According to the results of US assessment, the patients with PD positive synovitis (PD³1 in at least one joint) were randomly assigned to two groups; the patients increased the dose of MTX (intensive treatment group) or the patients continue their current treatment (coutinuous treatment group). The patients without active synovitis continued their current treatment (PD negative group). Standard radiographs of hands and forefeet were obtained at baseline, week 24 and 52. Radiological joint damage was assessed according to the modified total Sharp score (mTSS). The primary endpoint of the study was a change of mTSS after 52 weeks compared to the baseline.

Results:

Of 134 patients with clinical remission, PD positive synovitis was found in 101 patients (75.4%) at baseline. After the randomization, 51 patients were assigned to intensive treatment group and 50 patients to coutinuous treatment group. Thirty-seven patients in intensive treatment group (72.5%), 42 patients in coutinuous treatment group (84%) and 20 patients in PD negative group (60.6%) completed this study until week 52. Total PD score was significantly decreased inintensive treatment group comparing to coutinuous treatment group (-3.9 vs -2.0, p=0.019). The progression of mTSS was significantly suppressed in intensive treatment group compared to coutinuous treatment group at both week 24 (0.27 and 1.02, p=0.007) and week 52 (1.03 and 2.02, p=0.038). Especially, the progression of mTSS in patients treated with biologics in intensive treatment group (n=16) was suppressed as same as PD negative group (0.75 and 0.80, respectively) at week 52.

Conclusion:

In conclusion, clinical remission according to composite indexes allowed the presence of subclinical active synovitis that might induce structural joint damages. Subclinical active synovitis should be controlled by additional treatment and this results in the prevention of the joint damage progression. Evaluation of subclinical active synovitis by using high resolution US should be important even in patients achieving clinical remission and it should be treated more intensively.


Disclosure: T. Okano, None; K. Inui, Takeda Pharm. Co., Chugai Pharm. Co., Janssen Pharm. K.K., Abbvie GK, Astellas Pharma Inc., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharm. Co., 8; M. Tada, None; Y. Sugioka, None; K. Mamoto, None; T. Koike, Takeda Pharm. Co., Chugai Pharm. Co., Mitsubishi Tanabe Pharma Co., Eisai, Abbott Japan, Teijin Pharma, Banyu Pharm., and Ono Pharm., 8; H. Nakamura, Eisai Co.,Ltd., Daiichi Sankyo Co., Ltd., Eisai Co.,Ltd., Ono Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Asahi Kasei Pharma Co., Teijin Pharma Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Nippon Zoki Pharmace, 8.

To cite this abstract in AMA style:

Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H. Additional Intensive Treatment for Rheumatoid Arthritis Patients with Positive Power Doppler Signals Reduce the Radiological Joint Damage Even after Achieving Clinical Remission -SCRUM Study- [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/additional-intensive-treatment-for-rheumatoid-arthritis-patients-with-positive-power-doppler-signals-reduce-the-radiological-joint-damage-even-after-achieving-clinical-remission-scrum-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/additional-intensive-treatment-for-rheumatoid-arthritis-patients-with-positive-power-doppler-signals-reduce-the-radiological-joint-damage-even-after-achieving-clinical-remission-scrum-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology